MAZZEI, TERESITA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.601
EU - Europa 12.183
AS - Asia 8.905
SA - Sud America 1.251
AF - Africa 235
OC - Oceania 216
Continente sconosciuto - Info sul continente non disponibili 209
Totale 39.600
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.333
RU - Federazione Russa 4.120
SG - Singapore 2.550
IT - Italia 2.494
CN - Cina 2.165
PL - Polonia 1.561
HK - Hong Kong 1.349
IE - Irlanda 1.104
BR - Brasile 992
KR - Corea 894
VN - Vietnam 889
SE - Svezia 838
DE - Germania 482
FI - Finlandia 384
FR - Francia 378
UA - Ucraina 378
IN - India 292
GB - Regno Unito 221
AU - Australia 206
JP - Giappone 172
CA - Canada 153
TR - Turchia 123
JO - Giordania 109
AR - Argentina 107
BD - Bangladesh 81
NG - Nigeria 59
ES - Italia 52
ID - Indonesia 51
MX - Messico 51
CI - Costa d'Avorio 47
IQ - Iraq 46
ZA - Sudafrica 37
CH - Svizzera 35
EC - Ecuador 35
NL - Olanda 32
CO - Colombia 31
BE - Belgio 26
PE - Perù 23
UZ - Uzbekistan 23
VE - Venezuela 22
SA - Arabia Saudita 21
PK - Pakistan 19
AE - Emirati Arabi Uniti 18
CL - Cile 18
MA - Marocco 17
SC - Seychelles 17
PY - Paraguay 13
JM - Giamaica 12
PH - Filippine 12
NZ - Nuova Zelanda 10
AZ - Azerbaigian 9
IR - Iran 9
TN - Tunisia 9
TW - Taiwan 9
AL - Albania 8
AT - Austria 8
CZ - Repubblica Ceca 8
DZ - Algeria 8
KE - Kenya 8
TH - Thailandia 8
BJ - Benin 7
ET - Etiopia 7
LB - Libano 7
LT - Lituania 7
SY - Repubblica araba siriana 7
UY - Uruguay 7
CR - Costa Rica 6
EG - Egitto 6
HN - Honduras 6
KZ - Kazakistan 6
SV - El Salvador 6
BG - Bulgaria 5
GR - Grecia 5
NP - Nepal 5
OM - Oman 5
PA - Panama 5
PR - Porto Rico 5
TT - Trinidad e Tobago 5
BY - Bielorussia 4
DO - Repubblica Dominicana 4
GT - Guatemala 4
LU - Lussemburgo 4
MK - Macedonia 4
MY - Malesia 4
PS - Palestinian Territory 4
SN - Senegal 4
BB - Barbados 3
BO - Bolivia 3
DK - Danimarca 3
EU - Europa 3
HU - Ungheria 3
KW - Kuwait 3
NI - Nicaragua 3
PT - Portogallo 3
RS - Serbia 3
AM - Armenia 2
BH - Bahrain 2
EE - Estonia 2
IL - Israele 2
KG - Kirghizistan 2
Totale 39.362
Salva come PNG Salva come JPEG
Città #
Santa Clara 3.908
Singapore 1.759
Warsaw 1.554
Ashburn 1.324
Chandler 1.148
Dublin 1.101
Hong Kong 1.071
Fairfield 1.038
Seoul 861
Jacksonville 680
Hefei 608
Milan 519
Woodbridge 480
Cambridge 466
San Jose 461
Seattle 426
Houston 392
Wilmington 375
Beijing 335
The Dalles 310
Ho Chi Minh City 300
Buffalo 297
Lauterbourg 261
Los Angeles 261
Princeton 259
Rome 252
Ann Arbor 226
Melbourne 202
Hanoi 201
Boston 195
Boardman 187
Mumbai 170
Tokyo 169
Florence 158
Lawrence 151
Altamura 137
Dallas 129
Helsinki 115
Moscow 113
Medford 106
Shanghai 102
New York 101
Munich 95
São Paulo 82
Kent 76
Turin 70
Naples 69
San Diego 63
Bologna 58
Izmir 55
Abuja 54
Norwalk 51
Abidjan 47
Council Bluffs 47
Guangzhou 47
Dearborn 46
Redondo Beach 46
Turku 46
Figino 45
Paris 45
Haiphong 43
Da Nang 41
West Jordan 41
Orem 40
Palermo 40
Hillsboro 38
Toronto 38
Falls Church 36
Clifton 35
Bremen 32
Rio de Janeiro 31
Bern 28
Brooklyn 28
London 27
Montreal 27
Phoenix 27
Bengaluru 26
Frankfurt am Main 26
Bari 24
Chennai 24
Catania 23
Pune 23
Tianjin 23
Auburn Hills 22
Belo Horizonte 22
Yubileyny 22
Brussels 21
Chicago 21
Genoa 21
Jakarta 20
Tashkent 20
Venice 20
Andover 19
Denver 19
Dong Ket 18
Baghdad 17
Biên Hòa 17
Brasília 17
Johannesburg 17
Verona 17
Totale 25.001
Salva come PNG Salva come JPEG
Nome #
Cytotoxic activity of 3-nitropyrazolo[5,1-c][1,2,4]benzotriazine derivatives: a new series of anti-proliferative agents. 366
A survey on infection management practices in Italian ICUs 338
Farmaci antineoplastici - Farmaci inibitori della trasduzione del segnale - Farmaci inibitori di protein chinasi 337
Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil 332
How to manage aspergillosis in non-neutropenic intensive care unit patients. 299
A survey on infection management practices in Italian ICUs. 299
Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic Acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. 298
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin 282
Treatment of extensively drug-resistant Gram-negative infections in critically ill patients: Outcome of a consensus meeting at the 13th Asia-Pacific Congress of Clinical Microbiology and Infection, October 2012 277
Intraoperative positive fluid balance improves tissue diffusion of ceftizoxime. 276
Treatment options for methicillin-resistant Staphylococcus aureus (MRSA) infection: Where are we now? 268
Comportamenti sessuali e contraccezione 257
Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS) 253
Vancomycin in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: End of an era? 249
RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 240
A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 239
Marked variation of thymidylate synthase and folylpolyglutamate synthetase gene expression in human colorectal tumors. 236
Cellular pharmacology of gemcitabine. 228
Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors. 227
Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression 223
MOLECULAR CHARACTERIZATION OF ESTABLISHED HUMAN COLON CARCINOMA CELL LINES (HCT-8) MADE RESISTANT TO 5-FLUOROURACIL BY DIFFERENT SELECTION SCHEDULES 214
Stable disease in a patient with metastatic leiomyosarcoma treated with trabectedin 207
D13Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 207
Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 197
Cytotoxicity and DNA binding properties of a chloro glycylhistidinate gold(III) complex (GHAu). 195
Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors 194
Azithromycin concentrations in serum and bronchial secretions of patients with cystic fibrosis 186
Ertapenem peritoneal fluid concentrations in adult surgical patients. 186
Gender-related health in tuscany 183
Increased levels of CA 125 and CA 19·9 serum tumour markers following cyclic combined hormone replacement therapy 182
Retrospective analysis of 77 patients with ovarian cancer undergoing genetic testing for BRCA1 and BRCA2 mutations 182
Amoxicillin/clavulanic acid versus cefotaxime for antimicrobial prophylaxis in abdominal surgery: a randomized trial. 179
Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphisms in primary colorectal cancer patients 178
Chromosomal characterization of methotrexate-resistant human T-lymphoblast leukemia cells (CCRF-CEM) with impaired polyglutamylation. 177
Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer 176
Conclusions. Role of the oral Beta-lactams in the treatment of exacerbations of chronic bronchitis: critical analysis and therapeutics recommendations 176
Adverse drug reactions in oncoLogy: intEnsive monitoring program on drug toXicity of biotechnological medicatioNs anD taRget therapies in Oncologic patientS - the ALEXANDROS observational study 175
The most appropriate therapeutic strategy for acute lower respiratory tract infections: a Delphi-based approach. 175
The difficulties of polytherapy: examples from antimicrobial chemotherapy 175
Cytotoxic effects of gold(III) complexes on established human tumor cell lines sensitive and resistant to cisplatin 173
Cytotoxicity, DNA damage, and cell cycle perturbations induced by two representative gold(III) complexes in human leukemic cells with different cisplatin sensitivity 173
5-methyltetrahydrofolate (mTHF) induces monocytes differentiation in HL60 cells 169
5-methyltetrahydrofolate (MeTHF) enhances fluoropyrimidine cytotoxicity against human leukemia cells in vitro 168
Adverse effects of macrolide antibacterials. 166
Betalactam therapy and intestinal flora. 164
Methicillin-resistant Staphylococcus aureus infections: A review of the currently available treatment options 164
In vivo pharmacodynamic evaluation of clarithromycin in comparison to erythromycin. 164
Identification of pharmacogenomic markers of 5-fluorouracil-based chemotherapy in colorectal cancer 163
Farmacologia degli antibiotici nelle infezioni della cute e dei tessuti molli 163
ADVANCED COLORECTAL CANCER (ACRC) IN ELDERLY PATIENTS: EVALUATION OF THREE DIFFERENT OXALIPLATIN-BASED CHEMOTHERAPY REGIMENS - Session D: Colo-rectal Cancer 162
Differential inhibitory effects on human endometrial carcinoma cell growth of luteinizing hormone-releasing hormone analogues. 161
Concentration of moxifloxacin in plasma and tonsillar tissue after multiple administration in adult patients. 160
Quantitative analysis by polymerase chain reaction (PCR) of genes involved in resistance to cytotoxic antimetabolites 159
Evaluation of methotrexate (MTX) sensitivity by an ATP bioluminescence assay in human leukemia cells 159
Gold(III) Complexes with Bipyridyl Ligands: Solution Chemistry, Cytotoxicity and DNA Binding Properties 158
[Plasma and tissue antibiotic concentrations: what is their prognostic value?] 157
Gold(III) complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold(III) compounds. 156
Intra-arterial chemotherapy with 5-fluorouracil and 5-methyltetrahydrofolate in the treatment of unresectable liver metastases from colorectal cancer 156
Adjuvant therapy of colorectal carcinoma with 5-fluorouracil (5-FU) and l-folinic acid (l-LV) alone or with levamisole (LEV) or interferon alpha2a (IFN alpha2a). 155
Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum 155
Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections. 154
Adjuvant therapy of colorectal carcinoma with 5-fluorouracil (5-FU) and l-folinic acid (l-LV) alone or combined with levamisole (LEV) or interferon alpha2a (IFN alpha2a). Preliminary toxicological results of a multicenter study of the Gruppo Oncologico-Chirurgico Cooperativo Italiano (GOCCI) 153
The penetration of intramuscular cefotetan disodium into human extravascular fluid and maternal milk secretion. 153
Therapeutic recommendations of the multidisciplinary group. 153
Antimicrobial prophylaxis in prosthetic joint implant surgery: a comparative multicenter trial between teicoplanin and cefazolin 152
Induction of differentiation of HL-60 cells along the monocytic pathway by 5-methyltetrahydrofolate. 152
Marked variation thymidylate synthase (TS) and folylpolyglutamate synthetase (FPGS) gene expression in human colorectal cancer 151
Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation. 151
Pharmacological rationale for antibiotic treatment of intra-abdominal infections. 150
Antimicrobial chemoimmunoprophylaxis in colorectal surgery with cefotetan and thymostimulin: prospective, controlled multicenter study. Italian Study Group on Antimicrobial Prophylaxis in Abdominal Surgery. 150
Phase I clinical trial of a new alkylating agent, PTT-119 148
Pharmacokinetics and endocrine effects of leuprolide depot in advanced prostatic cancer: a dose-response analysis 148
Pharmacokinetics of melphalan (L-PAM) during hyperthermic perfusion in patients with melanoma of the limbs 148
Pharmacokinetic evaluation of meropenem and imipenem in critically-ill patients with sepsis. 148
Analisi cariologica di linee cellulari leucemiche umane CCRF-CEM resistenti al metotressato (MTX) per alterata poliglutammilazione. 148
Etiology issues and problems of antibiotic resistance 147
Adjuvant therapy of colorectal carcinoma with 5-fluorouracil and l-folinic acid alone or combined with levamisole or interferon-alfa2a. Preliminary toxicological results of a multicenter study of the Italian Cooperative Oncological-Surgical Group (GOCCI) 146
Comparative in vitro activity of the new oxazolidinones DuP 721 and DuP 105 against staphylococci and streptococci. 146
Comparative pharmacokinetic evaluation of ceftriaxone and cefotaxime in coincidence for short-term antimicrobial prophylaxis in surgery 146
Biochemical modulation of fluoropyrimidines by antifolates and folates in an in vitro model of human leukemia. 145
Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphysms in primary colorectal cancer patients. 145
Amikacin in obstetric, gynecologic, and neonatal infections: laboratory and clinical studies. 145
Identification of pharmacogenomic markers of 5-fluorouracil-based chemotherapy in colorectal cancer 145
Pharmacokinetics of dirithromycin in patients with mild or moderate cirrhosis 144
Effects of 5-methyltetrahydrofolate on the activity of fluoropyrimidines against human leukemia (CCRF-CEM) cells. 143
The pharmacokinetics and pharmacodynamics of the carbapenems: focus on doripenem 143
Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphisms in primary colorectal cancer patients 143
Enhancement of fluoropyrimidine cytotoxicity by 5-methyltetrahydrofolate in a human leukemia cell line, CCRF-CEM. 142
A randomized multicenter study comparing 5-fluorouracil (5-FU) and l-folinic acid (L-LV) alone or with levamisole (LEV) or interferon alpha2a (IFNalpha2a) as adjuvant therapy for colorectal cancer 142
Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. 141
Mechanisms of methotrexate (MTX) resistance in human colon carcinoma cells DLD-1 140
Quantitation of intratumoral thymidylate synthase (TS) and folylpolyglutamate synthetase (FPGS) gene expression by the Polymerase Chain Reaction (PCR): marked variation among human colorectal cancer patients 140
Comparative in vitro activity of ciprofloxacin against methicillin-resistant staphylococci 140
Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers 140
Efficacy of 3-(p-fluorofenyl)-L-alanyl-3-m-bis(2-chloroethyl)amino-phenyl-L-methionine ethoxy HCl (PTT-119) on human leukemia cell lines 140
Pharmacological aspects of the antibiotics used for urological diagnostic procedures 140
Antibiotic-induced release of bacterial cell wall components in the pathogenesis of sepsis and septic shock: a review. 139
Cefodizime in skin suction blister fluid and serum following a single intravenous or intramuscular dose in adult patients. 138
Description of the disease and diagnostic and epidemiologic aspects 138
Ciprofloxacin inhibition of cefoxitin betalactamase induction in an Enterobacter cloacae strain. 138
Totale 18.288
Salva come PNG Salva come JPEG
Categoria #
all - tutte 109.921
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 109.921
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.448 0 212 45 95 45 45 47 110 58 34 315 442
2022/20234.514 404 491 145 426 465 919 618 279 516 27 128 96
2023/20241.648 98 187 346 84 117 235 67 337 21 63 42 51
2024/202511.429 471 1.226 679 1.694 3.212 1.601 167 550 650 244 443 492
2025/202612.488 1.401 1.940 1.257 1.117 1.184 392 1.366 541 753 564 263 1.710
2026/2027388 369 19 0 0 0 0 0 0 0 0 0 0
Totale 39.600